Apixaban Has Lower Bleeding Risk for Initial Anticoagulation for Venous Thromboembolism
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 5, 2023 -- Apixaban has a lower bleeding risk than warfarin or rivaroxaban during initial treatment for patients with venous thromboembolism (VTE), according to a study published online Aug. 28 in the Journal of Internal Medicine.
Katarina Glise Sandblad, from the University of Gothenburg in Sweden, and colleagues compared major bleeding rates by choice of anticoagulation during the initial six months of treatment and extended treatment (up to five years) for VTE. The analysis included cancer-free patients with a first-time VTE between 2014 and 2020.
The researchers found that during initial treatment, major bleeding rates were 3.86 per 100 patient-years for warfarin, 2.93 for rivaroxaban, and 1.95 for apixaban, yielding adjusted hazard ratios (aHRs) of 0.89 (95 percent confidence interval [CI], 0.71 to 1.12) for rivaroxaban versus warfarin, 0.55 (95 percent CI, 0.43 to 0.71) for apixaban versus warfarin, and 0.62 (95 percent CI, 0.50 to 0.76) for apixaban versus rivaroxaban. Major bleeding rates during extended treatment were 1.55 per 100 patient-years for warfarin, 1.05 for rivaroxaban, and 0.96 for apixaban, with aHRs of 0.72 (95 percent CI, 0.53 to 0.99) for rivaroxaban versus warfarin, 0.60 (95 percent CI, 0.44 to 0.82) for apixaban versus warfarin, and 0.85 (95 percent CI, 0.64 to 1.12) for apixaban versus rivaroxaban. During both initial and extended treatment, previous bleeding and increasing age were risk factors for bleeding.
“It is important to keep in mind that patients included in the analysis on extended treatment were free of major bleeding during initial treatment, which could contribute to the low bleeding incidence,” the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Rate of Venous Thromboembolism Increased With Cancer Surgery
FRIDAY, Feb. 2, 2024 -- The rate of venous thromboembolism is increased in association with cancer surgery, according to a study published online Feb. 2 in JAMA Network...
Clot Risk High With Oral Contraceptives for Those at Genetic Risk
FRIDAY, Dec. 1, 2023 -- Oral contraceptive (OC) use is associated with an increased risk for developing a venous thromboembolism (VTE), particularly among women with a high...
Link Explored for NSAID Use, Hormonal Contraception, VTE Risk
MONDAY, Sept. 11, 2023 -- In women of reproductive age, nonsteroidal anti-inflammatory drug (NSAID) use is associated with venous thromboembolism, with significantly more...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.